12:00 AM
Oct 07, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BMN-673: Phase III ongoing

Myriad Genetics Inc. (NASDAQ:MYGN, Salt Lake City, Utah) said BioMarin will use Myriad's BRACAnalysis in BioMarin's ongoing, open-label Phase III trial comparing 1 mg oral BMN 673 once daily vs. physician's choice of capecitabine, gemcitabine, eribulin or vinorelbine in 430 metastatic breast...

Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >